Allogene Therapeutics Valuation Multiples

Allogene Therapeutics Overview

About Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Founded

2017

HQ

Employees

229

Website

allogene.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $4K

EBITDA: ($198M)

EV

$396M

Valuation Multiples

Multiples.vc

Start free trial

Allogene Therapeutics Financials

Allogene Therapeutics reported last 12-month revenue of $4K and negative EBITDA of ($198M).

In the same LTM period, Allogene Therapeutics generated $4K in gross profit, ($198M) in EBITDA losses, and had net loss of ($191M).

Allogene Therapeutics P&L

In the most recent fiscal year, Allogene Therapeutics reported revenue of — and EBITDA of ($177M).

Allogene Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Allogene Therapeutics Stock Performance

Allogene Therapeutics has current market cap of $571M, and enterprise value of $396M.

Allogene Therapeutics' stock price is $2.54.

Allogene Therapeutics Valuation Multiples

Allogene Therapeutics trades at 112558.8x EV/Revenue multiple, and (2.0x) EV/EBITDA.

Allogene Therapeutics Financial Valuation Multiples

As of March 18, 2026, Allogene Therapeutics has market cap of $571M and EV of $396M.

Equity research analysts estimate Allogene Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Allogene Therapeutics has a P/E ratio of (3.0x).

Allogene Therapeutics Margins & Growth Rates

Allogene Therapeutics' revenue in the last 12 month grew by 128496%.

Allogene Therapeutics' revenue per employee in the last FY averaged $0.0M.

Allogene Therapeutics' rule of 40 is (5501174%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Allogene Therapeutics' rule of X is (5308430%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Allogene Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Allogene Therapeutics M&A Activity

Allogene Therapeutics acquired XXX companies to date.

Last acquisition by Allogene Therapeutics was on XXXXXXXX, XXXXX. Allogene Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Allogene Therapeutics Investment Activity

Allogene Therapeutics invested in XXX companies to date.

Allogene Therapeutics made its latest investment on XXXXXXXX, XXXXX. Allogene Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).